MAPT and Alzheimer disease: Research is ongoing to develop new and more sensitive biomarkersthat can detect AD pathology in its earliest stages, even before symptomsappear, when treatments are most effective.113,356 Noninvasive diagnostic tests are showing great promise in detectingβ-amyloid and tau protein biomarkers equivalent or superiorto FDA-approved CSF tests in the detection of AD pathology.111 These diagnostic assays, more easily accessible,will help alleviate the bottleneck and unmet needs of healthcare professionalsand patients in evaluating them for AD.